As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage ...

Novartis (SWX:NOVN) has recorded its 29th consecutive annual dividend increase, extending a nearly three decade payout track ...

Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss.

NHS Scotland has approved a one-time CRISPR gene therapy for severe sickle cell disease, offering durable reduction in vaso-occlusive crises for eligible patients.

The global gene therapy market is experiencing rapid expansion, driven by advancements in CRISPR and viral vectors. The ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on ...

US biotech firm Fractyl Health is developing Rejuva, an experimental gene therapy that may mimic GLP-1 drugs for years after ...

A single one-time gene therapy could free patients with α-thalassemia, a rare and debilitating blood disorder, from the burden of lifelong transfusions. A single one-time gene therapy could free ...

Gene therapy approaches include gene replacement, suppression, and editing, each matched to specific genetic mechanisms in hereditary hearing loss. Preclinical studies in rodent models show promise, ...

To discover more about Nature’s Fynd, visit. To learn about their remarkable nutritional fungi protein and fermentation ...

Driven by Rising Demand for Advanced Cell Therapies, Including CAR T, the Market Expands as Key Processing Steps from Collection to Cryopreservation Ensure Quality and Functionality Across Clinical ...